65271-80-9
65271-80-9 結(jié)構(gòu)式
基本信息
米托蒽醌
米托恩醌
MITOXANTRONE
1,4-dihydroxy-5,8-bis(2-((2-hydroxyethyl)amino)ethylamino)-9,10-anthracenedi
5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino)-1,4-dihydroxy-anthraquinon
5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino)-1,4-dihydroxyanthraquinone
9,10-anthracenedione,1,4-dihydroxy-5,8-bis((2-((2-hydroxyethyl)amino)ethyl)a
dihydroxyanthraquinone
mitoxanthrone
nsc279836
MitoxantroneBase
Mitoxantrone Hcl 70476-82-3 / Base
PharmasubstanceEP4
1,4-Dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-9,10-anthracenedione
NSC-27983
9,10-Anthracenedione, 1,4-dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-
1,4-dihydroxy-5,8-bis(2-((2-hydroxyethyl)amino)ethylamino)-9,10-anthrace nedimitoxantrone
MITOXANTRONUM AND THE INTERMEDIATES
Mitoxantrone (base and/or unspecified salts)
MITOXANTRONUM
1,4-Dihydroxy-5,8-bis[2-[(2-hydroxyethyl)amino]ethylamino]-9,10-anthraquinone
物理化學(xué)性質(zhì)
安全數(shù)據(jù)
應(yīng)用領(lǐng)域
制備方法
81-59-4
111-41-1
65271-80-9
1. 在室溫下，于250 mL三頸燒瓶中加入10.5 g 1,4,5,8-四羥基-2,3-二氫蒽-9,10-二酮，隨后在氮?dú)饣驓鍤獗Ｗo(hù)下對(duì)燒瓶進(jìn)行抽真空處理。 2. 抽真空后，向燒瓶中通入空氣，加入59 mL 1,4-二惡烷并啟動(dòng)攪拌，使1,4,5,8-四羥基-2,3-二氫蒽-9,10-二酮完全溶解。 3. 將2.38 g N-(2-羥乙基)乙二胺加入恒壓滴液漏斗中，緩慢滴加到上述溶液中，滴加過程中持續(xù)攪拌，滴加時(shí)間為14分鐘，滴加完畢后得到糊狀粘稠液體。 4. 將反應(yīng)混合物置于53℃水浴中加熱，反應(yīng)2.2小時(shí)，反應(yīng)結(jié)束后得到藍(lán)棕色或藍(lán)紫色油狀液體，記為產(chǎn)物D。 5. 將產(chǎn)物D轉(zhuǎn)移至帶塞的容器中，加入170 mL無水乙醇，記錄液體體積。將容器置于59℃水浴中，通入經(jīng)無水硫酸鈣干燥的氧氣，緩慢氧化5.5小時(shí)，直至反應(yīng)液變?yōu)榱了{(lán)色。 6. 將亮藍(lán)色液體冷卻至室溫，補(bǔ)充乙醇至記錄的體積，室溫靜置30小時(shí)后，進(jìn)行真空過濾，得到藍(lán)色晶體產(chǎn)物E。 API的精制步驟： 1. 在燒杯中按絕對(duì)乙醇與正己烷體積比3:1配制180 mL混合溶劑。 2. 稱取9 g產(chǎn)物E，加入三頸瓶中，倒入上述混合溶劑，54℃水浴中攪拌至完全溶解。加入活性炭，持續(xù)攪拌并加熱至68℃回流22分鐘。熱回流結(jié)束后立即減壓過濾，濾液冷卻后冰浴過夜結(jié)晶，真空過濾得到藥物晶體。 3. 重新配制混合溶劑，用其對(duì)藥物晶體進(jìn)行多次洗滌，直至獲得無可見紅棕色、具有清晰光澤且粒度均勻的藍(lán)色晶體。洗滌完成后，將晶體于105℃恒溫干燥箱中干燥1.9小時(shí)，得到精制藥物鹽酸米托蒽醌。通過HPLC-UV測定，收率為38%。
參考文獻(xiàn)：
[1] Patent: CN108395379, 2018, A. Location in patent: Paragraph 0023; 0025-0077
| 報(bào)價(jià)日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱 | CAS號(hào) | 包裝 | 價(jià)格 |
| 2025/05/22 | HY-13502 | 米托蒽醌 Mitoxantrone | 65271-80-9 | 25 mg | 371元 |
| 2025/05/22 | HY-13502 | 米托蒽醌 Mitoxantrone | 65271-80-9 | 10mM * 1mLin DMSO | 408元 |
| 2025/05/22 | HY-13502 | 米托蒽醌 Mitoxantrone | 65271-80-9 | 50mg | 515元 |
常見問題列表
|
PKC 8.5 μM (IC 50 ) |
Topoisomerase II
|
Mitoxantrone inhibits PKC in a competitive manner with respect to histone H1, and its K i value is 6.3 μM and in a non-competitive manner with respect to phosphatidylserine and ATP. Treatment of B-CLL cells for 48 h with mitoxantrone (0.5 μg/mL) induces a decrease in cell viability. Mitoxantrone induces DNA fragmentation and the proteolytic cleavage of poly(ADP-ribose) polymerase (PARP), demonstrating that the cytotoxic effect of mitoxantrone is due to induction of apoptosis. Mitoxantrone shows cytotoxicity to human breast carcinoma cell lines MDA-MB-231 and MCF-7 with IC 50 values of 18 and 196 nM, respectively.
Mitoxantrone given IP at the optimal dose (1.6 mg/kg/day; as a free base) produces a statistically significant number of 60-day survivors (curative effect) in mice with IP implanted L1210 leukemia. In SC implanted Lewis lung carcinoma, mitoxantrone and ADM administered IV also shows effective antitumor activities and produces a 60% and a 45% ILS, respectively..